Last reviewed · How we verify
NCT05583604
Managed Access Programs for AIN457, Secukinumab
trial testing secukinumab in Hidradenitis Suppurativa (HS). Available.
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- secukinumab (secukinumab) — full drug profile →
Conditions studied
- Hidradenitis Suppurativa (HS) — all drugs for Hidradenitis Suppurativa (HS) →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
12 and older, any sex, with Hidradenitis Suppurativa (HS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.
Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. · · 2025 · cited 8× · PMID 39604776 · DOI 10.1007/s40259-024-00687-w
Verify or expand the search:
- PubMed search for NCT05583604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of secukinumab
Trials testing the same drug.
- NCT06444087 — Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation · active not recruiting
- NCT05921994 — Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adul · active not recruiting
- NCT05155098 — 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Patte · completed
- NCT04894890 — A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adu · completed
- NCT05677542 — Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intel · completed
Other recruiting trials for Hidradenitis Suppurativa (HS)
Currently open trials in the same condition.
- NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
- NCT07287644 — A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 2, PHASE3 · recruiting
- NCT07155239 — 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) · Phase 1 · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
- NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05583604 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing